靶向磷脂酰肌醇蛋白聚糖-3的肽结合物作为肝细胞癌诊疗一体化药物
磷脂酰肌醇蛋白聚糖-3(GPC3)在肝细胞癌中显著上调而正常组织表达极低,本研究开发了新型大环肽结合物DOTA-RYZ-GPC3(RAYZ-8009),可通过螯合不同放射性核素实现靶向诊疗。体外实验显示RAYZ-8009对人、小鼠、犬和食蟹猴来源的GPC3蛋白具有高结合亲和力,177Lu-RAYZ-8009在肝细胞癌异种移植瘤中显示持续肿瘤摄取和快速肾脏清除,177Lu和225Ac标记的RAYZ-8009单药及联合仑伐替尼均实现了显著且持久的肿瘤消退和生存获益。结论认为临床前数据表明RAYZ-8009有潜力作为GPC3阳性肝细胞癌患者的诊疗一体化药物。
要点
- RAYZ-8009是一种靶向GPC3的大环肽结合物,可螯合不同放射性核素用于诊疗一体化。
- 177Lu-RAYZ-8009在肝细胞癌异种移植瘤中显示持续肿瘤摄取和快速肾脏清除。
- 177Lu和225Ac标记的RAYZ-8009单药及联合仑伐替尼均实现显著且持久的肿瘤消退和生存获益。
核心结论
- 临床前体外和体内数据表明RAYZ-8009有潜力作为GPC3阳性肝细胞癌患者的诊疗一体化药物。
研究设计与样本
- 研究为临床前体外和体内实验,包括结合亲和力测定、放射性配体结合实验、细胞内化实验、体内生物分布研究以及肝细胞癌异种移植瘤的单药和联合治疗实验。
主要发现
- RAYZ-8009对人、小鼠、犬和食蟹猴来源的GPC3蛋白具有高结合亲和力,且不结合其他磷脂酰肌醇蛋白聚糖家族成员。
- 在GPC3阳性HepG2细胞中确认了强效细胞结合,且不受同位素切换影响;RAYZ-8009与HepG2细胞结合后实现了高效内化。
- 177Lu-RAYZ-8009的生物分布研究显示持续肿瘤摄取和快速肾脏清除,其他正常组织摄取极少或无摄取;在原位肝细胞癌肿瘤中也显示肿瘤特异性摄取,周围肝组织无摄取。
- 177Lu和225Ac标记的RAYZ-8009单药及联合仑伐替尼在GPC3阳性肝细胞癌异种移植瘤中均实现了显著且持久的肿瘤消退和生存获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glypican-3 (GPC3) is a membrane-associated glycoprotein that is significantly upregulated in hepatocellular carcinomas (HCC) with minimal to no expression in normal tissues. The differential expression of GPC3 between tumor and normal tissues provides an opportunity for targeted radiopharmaceutical therapy to treat HCC, a leading cause of cancer-related deaths worldwide. Methods: DOTA-RYZ-GPC3 (RAYZ-8009) comprises a novel macrocyclic peptide binder to GPC3, a linker, and a chelator that can be complexed with different radioisotopes. The binding affinity was determined by surface plasma resonance and radioligand binding assays. Target-mediated cellular internalization was radiometrically measured at multiple time points. In vivo biodistribution, monotherapy, and combination treatments with 177Lu or 225Ac were performed on HCC xenografts. Results: RAYZ-8009 showed high binding affinity to GPC3 protein of human, mouse, canine, and cynomolgus monkey origins and no binding to other glypican family members. Potent cellular binding was confirmed in GPC3-positive HepG2 cells and was not affected by isotope switching. RAYZ-8009 achieved efficient internalization on binding to HepG2 cells. Biodistribution study of 177Lu-RAYZ-8009 showed sustained tumor uptake and fast renal clearance, with minimal or no uptake in other normal tissues. Tumor-specific uptake was also demonstrated in orthotopic HCC tumors, with no uptake in surrounding liver tissue. Therapeutically, significant and durable tumor regression and survival benefit were achieved with 177Lu- and 225Ac-labeled RAYZ-8009, as single agents and in combination with lenvatinib, in GPC3-positive HCC xenografts. Conclusion: Preclinical in vitro and in vivo data demonstrate the potential of RAYZ-8009 as a theranostic agent for the treatment of patients with GPC3-positive HCC.
引用
- Lin F, Clift R, Ehara T, et al. Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma. J Nucl Med. 2024. PMID: 38423788. doi:10.2967/jnumed.123.266766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。